GAITHERSBURG, Md., Jan. 03, 2022 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral and a poster presentation on pemvidutide, the Company’s novel, investigational GLP-1/Glucagon dual receptor agonist under development for the treatment of obesity and non-alcoholic steatohepatitis (NASH), the most severe form of non-alcoholic fatty liver disease (NAFLD). The presentations will take place at the NASH-TAG Conference, which is being held January 6-8, 2022, in Park City, Utah. Details for the oral presentation are as follows:
| Title: | A placebo-controlled, double-blind, first-in-human study of Pemvidutide (ALT-801), a novel GLP-1/glucagon dual receptor agonist for the treatment of NASH and obesity |
| Presenter: | Scott Harris, M.D., Chief Medical Officer, Altimmune, Inc. |
| Date/Time: | Saturday, January 8, 2022 at 8:10 am Mountain Time |
A copy of Dr. Harris’ presentation and poster will be accessible on the Events section of the Altimmune website.
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (pemvidutide), and chronic hepatitis B (HepTcell™). For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Investor & Media Contacts:
Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com
Marie-Claude Jacques appointed Senior Vice President, Global Sales; Antwan Gipson joins as Senior Vice President,…
Marie-Claude Jacques appointed Senior Vice President, Global Sales; Antwan Gipson joins as Senior Vice President,…
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood…
TORONTO, ONTARIO / ACCESS Newswire / December 22, 2025 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum…
NORTHAMPTON, MA / ACCESS Newswire / December 22, 2025 / DaVita:For individuals managing chronic kidney…
VANCOUVER, BC AND LAS VEGAS, NV / ACCESS Newswire / December 22, 2025 / Ovation…